CYTO — Altamira Therapeutics Ltd.

Summary of Altamira Therapeutics Q2 2024 Earnings Call

1. Key Financial Results and Metrics

• Total Operating Loss: $3.9 million for H1 2024, slightly up from $3.6 million in H1 2023.
• Net Loss from Continuing Operations: $4.3 million, a 4% decrease from $4.5 million in H1 2023.
• Research and Development Expenses: Increased by 32.6% to $2 million.
• General and Administrative Expenses: Decreased by 11.7% to $2 million.
• Cash Used in Operations: Decreased from $8.4 million in H1 2023 to $3.2 million in H1 2024.
• Cash and Cash Equivalents: $65,000 as of June 30, 2024, compared to $55,000 in the same period last year.
• Shareholders' Equity: $6.3 million as of June 30, 2024, down from $7.7 million at year-end 2023.
• Public Offering: Raised $4 million gross proceeds, netting $3.3 million, with potential additional funding of up to $8 million linked to development milestones.

2. Strategic Updates and Business Highlights

• RNA Delivery Focus: Progress in the RNA delivery sector with the OligoPhore and SemaPhore platforms, showing promising in vivo data for cancer treatments.
• Partnerships: Collaborations with Heqet Therapeutics and Univercells Group to explore cardiac regeneration and mRNA vaccine delivery, respectively.
• Legacy Asset Management: Divested part of the Bentrio nasal spray business while retaining a 49% stake; ongoing efforts to partner AM-125 for vertigo treatment.
• Corporate Restructuring: Streamlined operations by merging subsidiaries and transitioning to a more focused RNA delivery business model.

3. Forward Guidance and Outlook

• Cash Needs for 2024: Expected to be between $5.8 million to $7 million, slightly lower than initial estimates.
• Development Timeline: Aiming for an Investigational New Drug (IND) filing for AM-401 and AM-411 by 2026, with plans to out-license these products after Phase 1 trials.
• Revenue Growth Anticipation: Significant revenue expected from Bentrio's expansion into new markets, particularly in Mainland China and Scandinavia, starting in 2025.

4. Bad News, Challenges, or Points of Concern

• Cash Position: Despite recent fundraising, cash reserves remain low, which could pose risks to operational sustainability.
• Increased R&D Costs: Rising expenses in R&D could impact overall financial health if not matched by revenue growth.
• Market Competition: The competitive landscape in RNA delivery and therapeutics remains challenging, especially with larger companies potentially scaling back R&D efforts.
• Dependency on Milestones: Future funding tied to specific development milestones introduces uncertainty, as there is no guarantee these will be met.

5. Notable Q&A Insights

• Marketing Strategy for Bentrio: Emphasis on building relationships with healthcare professionals and leveraging social media for product awareness in new markets.
• Impact of Larger mRNA Companies' Budget Cuts: CEO Thomas Meyer suggested that while larger firms may adjust their focus, the long-term potential for mRNA therapeutics remains strong, indicating a continued belief in the sector's growth despite fluctuations in larger players' strategies.

This summary encapsulates the key points from the earnings call, highlighting both the progress and challenges faced by Altamira Therapeutics as they navigate their strategic repositioning and financial landscape.